Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Eija Hirsi"'
Autor:
Ilkka Vihriälä, Jari Punkkinen, Tero Ylisaukko-oja, Taina Sipponen, Eija Hirsi, Christian Nielsen, Jyrki Tillonen, Markku Pajala, Jouni Silvennoinen, Ville Liukkonen, Mikko Kellokumpu, Jari Jokelainen, Henna Rautiainen, Veikko Moilanen, Hans Henricson, Hannu Sulonen, Mirva Esterinen, Timo Blomster, Kari Toljamo, Klaus Tamminen, Pauliina Molander, Airi Jussila, Jaakko Aaltonen, Juha Kuisma, Petri Mäkelä, Kalle Hakala, Margus Lääne, Kimmo Salminen, Sauli Herrala, Ulla-Maija Suhonen, Mika Puhto, Markku Peräaho, Heikki Nuutinen
Publikováno v:
Scandinavian Journal of Gastroenterology. 53:158-167
Objectives: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9bb6f87c8c3b92c84b454447a30170
https://doi.org/10.1080/00365521.2017.1416160
https://doi.org/10.1080/00365521.2017.1416160
Autor:
Kalle Hakala, C Wennerström, Eija Hirsi, Moilanen, Mikko Heikura, Ilkka Vihriälä, Jyrki Tillonen, C G af Björkesten, Karri T Utriainen, Taru Hallinen, Urpo Nieminen, Heikki Nuutinen, Tuire Ilus, Ulla-Maija Suhonen, Erkki Soini, Ritva Koskela, Mikko Kellokumpu, Airi Jussila, Christian Nielsen, Anja Eberl, Inka Koskinen, Andras Borsi, R Nissinen, Taina Sipponen, Markku Heikkinen, M Koivunen
Publikováno v:
Journal of Crohn's and Colitis. 14:S434-S435
Background Real-life long-term evidence on ustekinumab treatment response in patients with Crohn’s disease (CD) is scarce. We performed a retrospective non-interventional nationwide chart review study of dosing and long-term clinical outcomes in Fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32b806415ff67d89e888beede7fd909d
https://doi.org/10.1093/ecco-jcc/jjz203.628
https://doi.org/10.1093/ecco-jcc/jjz203.628
Autor:
Taina Sipponen, Anja Eberl, Karri T Utriainen, Taru Hallinen, Ilkka Vihriälä, Jyrki Tillonen, Inka Koskinen, Andras Borsi, Christian Nielsen, Ulla-Maija Suhonen, Eija Hirsi, R Nissinen, C Wennerström, Heikki Nuutinen, M Koivunen, Mikko Kellokumpu, Clas-Göran af Björkesten, Erkki Soini, Markku Heikkinen, Veikko Moilanen
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn?s Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::051170f4bddc4cdc187d73015a2d3579
http://hdl.handle.net/10138/306944
http://hdl.handle.net/10138/306944
Autor:
Ritva Koskela, Mikko Kellokumpu, Mikko Heikura, Taru Hallinen, Christian Nielsen, C Wennerström, Urpo Nieminen, M Koivunen, Inka Koskinen, Ilkka Vihriälä, C G af Björkesten, Kalle Hakala, Eija Hirsi, Anja Eberl, Erkki Soini, Jyrki Tillonen, R Nissinen, Ulla-Maija Suhonen, Taina Sipponen, Tuire Ilus, Veikko Moilanen, Andras Borsi, Heikki Nuutinen, Markku Heikkinen, Karri T Utriainen, Airi Jussila
Publikováno v:
Journal of Crohn's and Colitis. 14:S066-S066
Background Real-life long-term evidence on ustekinumab treatment in patients with Crohn’s disease (CD) is limited. We performed a retrospective non-interventional nation-wide chart review study of dosing and long-term clinical outcomes in Finnish C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b679397501d4d9d1f07d8a9e44045e3d
https://doi.org/10.1093/ecco-jcc/jjz203.065
https://doi.org/10.1093/ecco-jcc/jjz203.065
Autor:
Klaus Tamminen, Mikko Kellokumpu, Tero Ylisaukko-oja, Sauli Herrala, Markku Peräaho, Taina Sipponen, Henna Rautiainen, Petri Mäkelä, Jari Jokelainen, Ulla-Maija Suhonen, Heikki Nuutinen, Markku Pajala, Mirva Esterinen, Margus Lääne, Mika Puhto, Christian Nielsen, Jyrki Tillonen, Veikko Moilanen, Juha Kuisma, Ville Liukkonen, Kalle Hakala, Pauliina Molander, Hannu Sulonen, Saku Torvinen, Jaakko Aaltonen, Jouni Silvennoinen, Hans Henricson, Ilkka Vihriälä, Eija Hirsi, Kari Toljamo, Airi Jussila, Jari Punkkinen, Timo Blomster, Kimmo Salminen
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 58
Limited data is available on vedolizumab combination therapies in real-world clinical practice. Here, we evaluated the concomitant corticosteroid, immunosuppressive, and 5-aminosalicylic acid utilization of inflammatory bowel disease (IBD) patients t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e3e084581707aa9c9a3ddfb0c44882
https://pubmed.ncbi.nlm.nih.gov/30755369
https://pubmed.ncbi.nlm.nih.gov/30755369